Pharmaron Beijing Co Ltd
SZSE:300759

Watchlist Manager
Pharmaron Beijing Co Ltd Logo
Pharmaron Beijing Co Ltd
SZSE:300759
Watchlist
Price: 27.09 CNY -1.67% Market Closed
Market Cap: 40.3B CNY
Have any thoughts about
Pharmaron Beijing Co Ltd?
Write Note

Pharmaron Beijing Co Ltd
Pre-Tax Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Pharmaron Beijing Co Ltd
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
Pharmaron Beijing Co Ltd
SZSE:300759
Pre-Tax Income
ÂĄ2.1B
CAGR 3-Years
10%
CAGR 5-Years
33%
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
Pre-Tax Income
ÂĄ9.9B
CAGR 3-Years
26%
CAGR 5-Years
31%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Pre-Tax Income
ÂĄ3.7B
CAGR 3-Years
3%
CAGR 5-Years
31%
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Pre-Tax Income
ÂĄ1.3B
CAGR 3-Years
-25%
CAGR 5-Years
8%
CAGR 10-Years
24%
M
MGI Tech Co Ltd
SSE:688114
Pre-Tax Income
-ÂĄ590.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
W
WuXi XDC Cayman Inc
HKEX:2268
Pre-Tax Income
ÂĄ359.6m
CAGR 3-Years
123%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Pharmaron Beijing Co Ltd
Glance View

Market Cap
40.3B CNY
Industry
Life Sciences Tools & Services

Pharmaron Beijing Co Ltd., a dynamic player in the biotech and pharmaceutical services sector, has carved a niche by capitalizing on the demand for comprehensive R&D services. Founded in 2004, the company emerged at a time when global pharmaceutical companies were grappling with skyrocketing research costs and the increasing complexity of drug development. Pharmaron offers a broad spectrum of services across the drug discovery and development pipeline, including laboratory services, chemistry, biology, and pharmacology, effectively monetizing its expertise by partnering with global pharmaceutical firms. By providing integrated solutions that cover the entire span of research, from preclinical development to commercial manufacturing, Pharmaron positions itself as an indispensable ally for companies aiming to streamline their product development journeys. The company’s revenue model thrives on long-term partnerships and collaborations with some of the industry's leading pharmaceutical and biotech firms. Using a client-centric approach, Pharmaron aligns its capabilities with customer needs, ensuring scalable and customizable service offerings. This close alignment not only enhances client satisfaction but also encourages repeat business, fostering a cycle of sustainable revenue growth. In recent years, Pharmaron has been expanding its geographical footprint and service capacity through strategic acquisitions and investments in state-of-the-art facilities and technologies, aiming to bolster its position in key markets across the US, Europe, and China. As the pharmaceutical landscape continues to evolve, Pharmaron leverages its robust R&D service portfolio and strategic alliances to maintain its growth trajectory amidst a backdrop of increasing globalization and technological advancement in the industry.

Intrinsic Value
39.38 CNY
Undervaluation 31%
Intrinsic Value
Price

See Also

What is Pharmaron Beijing Co Ltd's Pre-Tax Income?
Pre-Tax Income
2.1B CNY

Based on the financial report for Sep 30, 2024, Pharmaron Beijing Co Ltd's Pre-Tax Income amounts to 2.1B CNY.

What is Pharmaron Beijing Co Ltd's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 5Y
33%

Over the last year, the Pre-Tax Income growth was 20%. The average annual Pre-Tax Income growth rates for Pharmaron Beijing Co Ltd have been 10% over the past three years , 33% over the past five years .

Back to Top